Lexeo Therapeutics (NASDAQ:LXEO) Trading Up 3.6% - What's Next?

Lexeo Therapeutics, Inc. (NASDAQ:LXEO - Get Free Report)'s stock price shot up 3.6% during trading on Wednesday . The stock traded as high as $4.68 and last traded at $4.60. 550,115 shares traded hands during trading, an increase of 1% from the average session volume of 544,468 shares. The stock had previously closed at $4.44.

Wall Street Analyst Weigh In

Several brokerages have recently commented on LXEO. Leerink Partners decreased their price target on Lexeo Therapeutics from $19.00 to $18.00 and set an "outperform" rating on the stock in a research note on Monday, March 24th. Royal Bank Of Canada decreased their price target on Lexeo Therapeutics from $24.00 to $20.00 and set an "outperform" rating on the stock in a research note on Tuesday, March 25th. JPMorgan Chase & Co. reduced their target price on Lexeo Therapeutics from $16.00 to $10.00 and set an "overweight" rating on the stock in a research note on Friday, May 30th. Chardan Capital reduced their target price on Lexeo Therapeutics from $22.00 to $20.00 and set a "buy" rating on the stock in a research note on Tuesday, May 13th. Finally, HC Wainwright reduced their target price on Lexeo Therapeutics from $23.00 to $15.00 and set a "buy" rating on the stock in a research note on Friday, May 16th. Five investment analysts have rated the stock with a buy rating, According to data from MarketBeat, the company has an average rating of "Buy" and a consensus price target of $16.60.

Lexeo Therapeutics Trading Down 2.6%

The business has a fifty day moving average price of $3.65 and a 200 day moving average price of $3.96. The company has a market capitalization of $148.40 million, a PE ratio of -1.35 and a beta of 1.32. The company has a debt-to-equity ratio of 0.01, a quick ratio of 3.42 and a current ratio of 3.42.

Lexeo Therapeutics (NASDAQ:LXEO - Get Free Report) last announced its earnings results on Monday, May 12th. The company reported ($0.99) EPS for the quarter, missing the consensus estimate of ($0.80) by ($0.19). Analysts expect that Lexeo Therapeutics, Inc. will post -3.14 EPS for the current fiscal year.

Institutional Investors Weigh In On Lexeo Therapeutics

Several hedge funds have recently modified their holdings of the stock. Allostery Investments LP purchased a new stake in Lexeo Therapeutics during the 4th quarter worth approximately $33,000. Price T Rowe Associates Inc. MD purchased a new stake in Lexeo Therapeutics during the 4th quarter worth approximately $69,000. Wells Fargo & Company MN increased its holdings in Lexeo Therapeutics by 49.9% during the 4th quarter. Wells Fargo & Company MN now owns 11,156 shares of the company's stock worth $73,000 after purchasing an additional 3,714 shares during the last quarter. Ground Swell Capital LLC acquired a new position in shares of Lexeo Therapeutics in the 1st quarter worth approximately $80,000. Finally, Acadian Asset Management LLC acquired a new position in shares of Lexeo Therapeutics in the 1st quarter worth approximately $85,000. 60.67% of the stock is currently owned by hedge funds and other institutional investors.

Lexeo Therapeutics Company Profile

Lexeo Therapeutics, Inc operates as a clinical stage genetic medicine company that focuses on hereditary and acquired diseases. The company develops LX2006, which is an AAVrh10-based gene therapy candidate for the treatment of Friedreich's ataxia (FA) cardiomyopathy; LX2020, an AAVrh10-based gene therapy candidate for the treatment of plakophilin-2 arrhythmogenic cardiomyopathy; LX2021, a gene therapy candidate for the treatment of DSP cardiomyopathy associated with it; and LX2022, a gene therapy candidate for the treatment of hypertrophic cardiomyopathy, or HCM caused by TNNI3 gene.